Matches in Wikidata for { <http://www.wikidata.org/entity/Q64652441> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q64652441 description "clinical trial" @default.
- Q64652441 description "ensayu clínicu" @default.
- Q64652441 description "klinisch onderzoek" @default.
- Q64652441 description "клінічне випробування" @default.
- Q64652441 name "A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia" @default.
- Q64652441 type Item @default.
- Q64652441 label "A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia" @default.
- Q64652441 prefLabel "A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia" @default.
- Q64652441 P1050 Q64652441-C32AEE00-7615-42F7-A4E9-99E9391DB642 @default.
- Q64652441 P1132 Q64652441-05234C61-C030-4532-8839-8BBB52CF5D9F @default.
- Q64652441 P1476 Q64652441-F9BE01BC-5D7A-4CB8-9744-4EF4B2C81054 @default.
- Q64652441 P17 Q64652441-6C8BC4DB-B41A-43F5-AF8A-E822E8A9D343 @default.
- Q64652441 P17 Q64652441-6CBABF38-54C5-4AD0-8C11-9939736A22A7 @default.
- Q64652441 P17 Q64652441-780784A4-5E39-4758-9582-850DB0A0EA5B @default.
- Q64652441 P17 Q64652441-7E0E3A27-C8E2-4F27-91D2-806845EE9C51 @default.
- Q64652441 P17 Q64652441-EA98766D-FE1E-476F-A5B3-828B35AAFFDC @default.
- Q64652441 P2899 Q64652441-1DFE18BA-7803-4FBF-B96C-998EB777730C @default.
- Q64652441 P3098 Q64652441-429A86BA-E441-4CED-A176-2545143A7AB4 @default.
- Q64652441 P31 Q64652441-F3206BA0-1A2C-4462-9CD2-199AAC5C6B28 @default.
- Q64652441 P580 Q64652441-32D52267-C4A3-45B3-9D2E-4EA98D7AA9AE @default.
- Q64652441 P582 Q64652441-D27F88AD-965A-45B5-9EA9-F7F8167AF6D7 @default.
- Q64652441 P6099 Q64652441-52F1C021-A04F-41B6-85C5-9F96BDA5C822 @default.
- Q64652441 P6153 Q64652441-045F1E9D-4A90-4477-A681-712467E099AD @default.
- Q64652441 P6153 Q64652441-222CE21E-E4F6-41DB-9C74-5D7F651CE2AC @default.
- Q64652441 P6153 Q64652441-22922AE0-E53B-4DBC-B41E-AFEC0A1D0DF8 @default.
- Q64652441 P6153 Q64652441-36D52792-9B59-4C4A-886B-D01AF3FA35A9 @default.
- Q64652441 P6153 Q64652441-420AC211-EAE0-4663-9B6B-0F27EA18170E @default.
- Q64652441 P6153 Q64652441-B0A24CC2-29E7-45A4-AEE8-771CD0755996 @default.
- Q64652441 P6153 Q64652441-B41D568E-6BDE-4AED-89FD-AE0A696E94C9 @default.
- Q64652441 P6153 Q64652441-C55499B4-5231-41FF-96FF-BEB5061309C3 @default.
- Q64652441 P6153 Q64652441-E632415D-9997-451E-B998-3FEDEEAC8CFB @default.
- Q64652441 P6153 Q64652441-F402A990-F977-4F53-B9E1-D480C0AD1C80 @default.
- Q64652441 P8363 Q64652441-714AB42B-0664-4330-BD13-7E917E2EA40C @default.
- Q64652441 P859 Q64652441-372A745E-6EBE-4901-9E6A-64DDBA22CCCF @default.
- Q64652441 P1050 Q41112 @default.
- Q64652441 P1132 "+625" @default.
- Q64652441 P1476 "A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period" @default.
- Q64652441 P17 Q17 @default.
- Q64652441 P17 Q213 @default.
- Q64652441 P17 Q219 @default.
- Q64652441 P17 Q30 @default.
- Q64652441 P17 Q38 @default.
- Q64652441 P2899 "+18" @default.
- Q64652441 P3098 "NCT01192880" @default.
- Q64652441 P31 Q30612 @default.
- Q64652441 P580 "2010-11-01T00:00:00Z" @default.
- Q64652441 P582 "2014-07-01T00:00:00Z" @default.
- Q64652441 P6099 Q42824827 @default.
- Q64652441 P6153 Q1057199 @default.
- Q64652441 P6153 Q10906885 @default.
- Q64652441 P6153 Q10924832 @default.
- Q64652441 P6153 Q1108197 @default.
- Q64652441 P6153 Q168751 @default.
- Q64652441 P6153 Q16947 @default.
- Q64652441 P6153 Q30253940 @default.
- Q64652441 P6153 Q30269522 @default.
- Q64652441 P6153 Q30269791 @default.
- Q64652441 P6153 Q7488482 @default.
- Q64652441 P8363 Q78089383 @default.
- Q64652441 P859 Q212646 @default.